Trials / Completed
CompletedNCT00065429
Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer
A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing With BB-10901, Followed by a Phase II Efficacy Expansion
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- ImmunoGen, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was a Phase I/II trial primarily focused on efficacy of BB-10901 in relapsed small cell lung cancer and other solid tumors.
Detailed description
The Phase II efficacy expansion was restricted to SCLC patients with relapsed disease and the MTD was determined by the Phase I portion of the trial (60mg/m2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BB-10901 | I.V. Infusion - See "Arms" for dosage - Once/Week for three weeks - Until Progression of disease. |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2008-11-01
- Completion
- 2008-12-01
- First posted
- 2003-07-24
- Last updated
- 2012-07-18
- Results posted
- 2012-06-20
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00065429. Inclusion in this directory is not an endorsement.